Table 2.
A sampling of recommendations by public health organizations regarding COVID-19 vaccination in children.
| CDC [83] | JCVI [84,85,86,87,95] | WHO [14] | |||||
|---|---|---|---|---|---|---|---|
| Children 6 Months–4 Years Old | Children 5–11 Years Old | Adolescents 12–17 Years Old |
Children 5–11 Years Old | Adolescents 12–17 Years Old | Children 5–11 Years Old | Adolescents 12–17 Years Old | |
| Primary vaccination | Recommended for all individuals Dosing: three 3 µg BNT162b2 doses (≥3 weeks between doses 1 and 2 and ≥8 weeks between doses 2 and 3); two 25 µg mRNA-1273 doses (≥4–8 weeks between doses) |
Recommended for all individuals Dosing: two 10 µg BNT162b2 doses ≥3–8 weeks apart for those 5–11 years old; two 25 µg mRNA-1273 doses ≥4 weeks apart for those 5 years old; and two 50 µg mRNA-1273 doses ≥4–8 weeks apart for those 6–11 years old |
Recommended for all individuals Dosing: two 30 µg BNT162b2 doses ≥3–8 weeks apart; two 100 µg mRNA-1273 doses ≥4–8 weeks apart |
Should be offered to those in a clinical risk group or household contacts of immunosuppressed individuals Dosing: two 10 µg BNT162b2 doses 8 weeks apart |
Should be offered to all individuals Dosing: two 30 µg BNT162b2 doses ≥8 (at-risk individuals) or ≥12 weeks (healthy individuals) apart |
Countries should consider their specific epidemiologic and social context when considering vaccination of children and adolescents, with priority given to vaccination of adults and at-risk groups | |
| Additional dose | No recommendations given | Recommended for moderately and severely immunocompromised individuals Timing: ≥28 days after second dose |
Not recommended | Should be offered to those who were severely immunosuppressed at the time of their first or second dose Timing: generally ≥8 weeks after second dose |
No recommendations given | No recommendations given | |
| Booster dose | Not recommended | Recommended (for BNT162b2 only) Timing: ≥5 months after last primary dose |
Recommended (for BNT162b2 only) Timing: ≥5 months after last primary dose |
Not recommended | 12–15 years of age: should be offered to those in a clinical risk group, household contact of immunosuppressed individuals, or severely immunocompromised and received a third dose 16–17 years of age: should be offered to all individuals Timing: ≥3 months after last primary dose |
No recommendations given | No recommendations given |
CDC, US Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; JCVI, UK Joint Committee on Vaccination and Immunisation; WHO, World Health Organization.